EP
BPMC

Elkfork Partners’s Blueprint Medicines BPMC Stock Holding History

Elkfork Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$350K Hold
4,760
– – 0.01% 684
2019
Q2 		$449K Buy
+4,760
New +$393K 0.01% 608

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Elkfork Partners's BPMC Position: Q3 2019 in Review

Elkfork Partners held its Blueprint Medicines (BPMC) position steady in Q3 2019 at 4,760 shares worth $350K. The position accounts for 0.01% of the portfolio, ranked #684.

Elkfork Partners first reported a position in BPMC in Q2 2019 and has held it in 2 quarters since. The position peaked at $449K in Q2 2019. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

  • Elkfork Partners held 4,760 shares of Blueprint Medicines worth $350K as of Q3 2019.
  • Elkfork Partners left its Blueprint Medicines share count unchanged in Q3 2019.
  • Blueprint Medicines made up 0.01% of Elkfork Partners's portfolio in Q3 2019, its #684 holding.
  • Elkfork Partners first reported a position in Blueprint Medicines in Q2 2019 and has held it in 2 quarters since.
  • Elkfork Partners's Blueprint Medicines position peaked at $449K in Q2 2019.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.